Insulet SmartAdjust is an interoperable, automated glycemic control software that connects to an insulin pump and continuous glucose monitor to automatically adjust insulin delivery. The technology was previously approved only for management of Type 1 diabetes, according to an Aug. 26 news release from the FDA.
Individuals with Type 2 diabetes typically manage insulin levels by manually checking blood glucose levels and self-administering insulin one or more times a day.
The Insulet SmartAdjust technology was cleared through the FDA’s 510(k) premarket pathway.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
